NCT06060405View on ClinicalTrials.gov

Durvalumab and Oleclumab in Resectable PDAC

PHASE2RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 29, 2023

Primary Completion Date

October 30, 2026

Study Completion Date

October 30, 2026

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

Durvalumab

Durvalumab is a monoclonal antibody that blocks the interaction of PD-L1 with PD-1 on immune cells.

DRUG

Oleclumab

Oleclumab is a monoclonal antibody that binds to and inhibits the activity of CD73.

Trial Locations (1)

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER